



CPT® Proprietary Laboratory Analyses (PLA) Codes: Long Descriptors

It is important to note that further CPT Editorial Panel (Panel) or Executive Committee actions may affect these codes and/or descriptors. For this reason, code numbers and/or descriptor language in the CPT code set may differ at the time of publication. In addition, further Panel actions may result in gaps in code number sequencing.

Most recent changes to the CPT® Proprietary Laboratory Analyses (PLA) Long Descriptor document

- Addition of 4 PLA codes (0080U-0083U) and revision of one code and proprietary name (0008U) accepted at the November 2018 CPT Editorial Panel meeting.
- Addition of “.” between “C” and “*tropicalis*” in the code descriptor for code 0068U.
- Deleted codes in this document appear with a ~~strikethrough~~.

Proprietary laboratory analyses (PLA) codes describe proprietary clinical laboratory analyses and can be either provided by a single (“sole-source”) laboratory or licensed or marketed to multiple providing laboratories (eg, cleared or approved by the Food and Drug Administration [FDA]).

This subsection includes advanced diagnostic laboratory tests (ADLTs) and clinical diagnostic laboratory tests (CDLTs), as defined under the Protecting Access to Medicare Act (PAMA) of 2014. These analyses may include a range of medical laboratory tests including, but not limited to, multianalyte assays with algorithmic analyses (MAAA) and genomic sequencing procedures (GSP). The descriptor nomenclature follows, where possible, existing code conventions (eg, MAAA, GSP).

These codes are not required to fulfill the Category I criteria. The standards for inclusion in this section are:

- The test must be commercially available in the United States for use on human specimens and
- The clinical laboratory or manufacturer that offers the test must request the code.

For similar laboratory analyses that fulfill Category I criteria, see codes listed in the numeric 80000 series.

When a PLA code is available to report a given proprietary laboratory service, that PLA code takes precedence. The service should not be reported with any other CPT code(s) and other CPT code(s) should not be used to report services that may be reported with that specific PLA code. These codes encompass all analytical services required for the analysis (eg, cell lysis, nucleic acid stabilization, extraction, digestion, amplification, hybridization and detection). For molecular analyses, additional procedures that are required prior to cell lysis (eg, microdissection [codes 88380 and 88381]) may be reported separately.

Codes in this subsection are released on a quarterly basis to expedite dissemination for reporting. PLA codes will be published electronically on the AMA CPT website (www.ama-assn.org/practice-management/cpt-pla-codes), distributed via CPT data files on a quarterly basis, and, at a minimum, made available in print annually in the CPT codebook. Go to www.ama-assn.org/sites/default/files/media-browser/public/physicians/cpt/cpt-pla-codes-long.pdf for the most current listing.

All codes that are included in this section are also included in Appendix O, with the procedure’s proprietary name. In order to report a PLA code, the analysis performed must fulfill the code descriptor and must be the test represented by the proprietary name listed in Appendix O. In some instances, the descriptor language of PLA codes may be identical and the code may only be differentiated by the listed proprietary name in Appendix O. When more than one PLA has an identical descriptor, the codes will be denoted by the symbol “✕.”



Proprietary Name and Clinical Laboratory and/or Manufacturer	Code	Long Code Descriptor	Released to AMA Website	Effective Date	Publication
PreciseType [®] HEA Test, Immucor, Inc	●0001U	Red blood cell antigen typing, DNA, human erythrocyte antigen gene analysis of 35 antigens from 11 blood groups, utilizing whole blood, common RBC alleles reported	December 2, 2016	February 1, 2017	CPT [®] 2018
PolypDX [™] , Atlantic Diagnostic Laboratories, LLC, Metabolomic Technologies Inc	●0002U	Oncology (colorectal), quantitative assessment of three urine metabolites (ascorbic acid, succinic acid and carnitine) by liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring acquisition, algorithm reported as likelihood of adenomatous polyps	December 2, 2016	February 1, 2017	CPT [®] 2018
Overa (OVA1 Next Generation), Aspira Labs, Inc, Vermillion, Inc	●0003U	Oncology (ovarian) biochemical assays of five proteins (apolipoprotein A-1, CA 125 II, follicle stimulating hormone, human epididymis protein 4, transferrin), utilizing serum, algorithm reported as a likelihood score	December 2, 2016	February 1, 2017	CPT [®] 2018
Gram-Negative Bacterial Resistance Gene PCR Panel Mayo Clinic Check-Points Health BV, Wageningen, Netherlands	●0004U	Infectious disease (bacterial), DNA, 27 resistance genes, PCR amplification and probe hybridization in microarray format (molecular detection and identification of AmpC, carbapenemase and ESBL coding genes), bacterial culture colonies, report of genes detected or not detected, per isolate ▶(0004U has been deleted)◀	March 1, 2017 Deletion Released to AMA Website December 1, 2017	May 1, 2017 Deletion Effective January 1, 2018	CPT [®] 2018 Deletion Publication CPT [®] 2019
ExosomeDx [®] Prostate (IntelliScore), Exosome Diagnostics, Inc	●0005U	Oncology (prostate) gene expression profile by real-time RT-PCR of 3 genes (<i>ERG</i> , <i>PCA3</i> , and <i>SPDEF</i>), urine, algorithm reported as risk score	March 1, 2017	May 1, 2017	CPT [®] 2018

<p>Aegis-Drug-Ddrug, Drug-substance Identification and Interaction-Test, Aegis Sciences Corporation</p>	<p>▲0006U</p>	<p>PrescripDetection drug monitoring of interacting medications, substances, supplements and foods, 120 or more drugs and substances, analytes, definitive tandem mass spectrometry with chromatography, urine, qualitative report of presence (including quantitative levels, when detected) or absence of each drug or substance with mass spectrometry, urine, description and severity of potential each interactions, with identified substances, per date of service</p>	<p>June 1, 2018</p>	<p>July 1, 2018</p>	<p>CPT® 2019</p>
<p>ToxProtect, Genotox Laboratories LTD</p>	<p>●0007U</p>	<p>Drug test(s), presumptive, with definitive confirmation of positive results, any number of drug classes, urine, includes specimen verification including DNA authentication in comparison to buccal DNA, per date of service</p> <p>► (For additional PLA code with identical clinical descriptor, see 0020U. See Appendix O to determine appropriate code assignment) ◀</p>	<p>June 1, 2017</p>	<p>August 1, 2017</p>	<p>CPT® 2018</p>
<p>AmHPR® H.<i>elicobacter</i>pylori Antibiotic Resistance Next Generation Sequencing-Panel, American Molecular Laboratories, Inc</p>	<p>▲0008U</p>	<p>Helicobacter pylori detection and antibiotic resistance, DNA, 16S and 23S rRNA, gyrA, pbp1, rdxA and rpoB, next generation sequencing, formalin-fixed paraffin-embedded or fresh tissue <u>or fecal</u> <u>sample</u>, predictive, reported as positive or negative for resistance to clarithromycin, fluoroquinolones, metronidazole, amoxicillin, tetracycline, and rifabutin</p>	<p>June 1, 2017</p> <p>Revision Released to AMA Website November 30, 2018</p>	<p>August 1, 2017</p> <p>Revision Effective January 1, 2019</p>	<p>CPT® 2018</p> <p>Revision Publication CPT® 2020</p>
<p>DEPArray™ HER2, PacificDx</p>	<p>●0009U</p>	<p>Oncology (breast cancer), <i>ERBB2</i> (HER2) copy number by FISH, tumor cells from formalin-fixed paraffin-embedded tissue isolated using image-based dielectrophoresis (DEP) sorting, reported as <i>ERBB2</i> gene amplified or non-amplified</p>	<p>June 1, 2017</p>	<p>August 1, 2017</p>	<p>CPT® 2018</p>
<p>Bacterial Typing by Whole Genome Sequencing, Mayo Clinic</p>	<p>●0010U</p>	<p>Infectious disease (bacterial), strain typing by whole genome sequencing, phylogenetic-based report of strain relatedness, per submitted isolate</p>	<p>June 1, 2017</p>	<p>August 1, 2017</p>	<p>CPT® 2018</p>

Cordant CORE™, Cordant Health Solutions	●0011U	Prescription drug monitoring, evaluation of drugs present by LC-MS/MS, using oral fluid, reported as a comparison to an estimated steady-state range, per date of service including all drug compounds and metabolites	June 1, 2017	August 1, 2017	CPT® 2018
MatePair Targeted Rearrangements, Congenital, Mayo Clinic	●0012U	Germline disorders, gene rearrangement detection by whole genome next-generation sequencing, DNA, whole blood, report of specific gene rearrangement(s)	June 1, 2017	August 1, 2017	CPT® 2018
MatePair Targeted Rearrangements, Oncology, Mayo Clinic	●0013U	Oncology (solid organ neoplasia), gene rearrangement detection by whole genome next-generation sequencing, DNA, fresh or frozen tissue or cells, report of specific gene rearrangement(s)	June 1, 2017	August 1, 2017	CPT® 2018
MatePair Targeted Rearrangements, Hematologic, Mayo Clinic	●0014U	Hematology (hematolymphoid neoplasia), gene rearrangement detection by whole genome next-generation sequencing, DNA, whole blood or bone marrow, report of specific gene rearrangement(s)	June 1, 2017	August 1, 2017	CPT® 2018
OneOme RightMed Pharmacogenomic Test OneOme, LLC	●0015U	Drug metabolism (adverse drug reactions), DNA, 22 drug metabolism and transporter genes, real-time PCR, blood or buccal swab, genotype and metabolizer status for therapeutic decision support ▶(0015U has been deleted)◀	June 1, 2017 Deletion Released to AMA Website December 1, 2017	August 1, 2017 Deletion Effective January 1, 2018	CPT® 2018 Deletion Publication CPT® 2019
BCR-ABL1 major and minor breakpoint fusion transcripts, University of Iowa, Department of Pathology, Asuragen	●0016U	Oncology (hematolymphoid neoplasia), RNA, <i>BCR/ABL1</i> major and minor breakpoint fusion transcripts, quantitative PCR amplification, blood or bone marrow, report of fusion not detected or detected with quantitation	June 1, 2017	August 1, 2017	CPT® 2018



JAK2 Mutation, University of Iowa, Department of Pathology	●0017U	Oncology (hematolymphoid neoplasia), JAK2 mutation, DNA, PCR amplification of exons 12-14 and sequence analysis, blood or bone marrow, report of JAK2 mutation not detected or detected	June 1, 2017	August 1, 2017	CPT® 2018
ThyraMIR™, Interpace Diagnostics, Interpace Diagnostics	●0018U	Oncology (thyroid), microRNA profiling by RT-PCR of 10 microRNA sequences, utilizing fine needle aspirate, algorithm reported as a positive or negative result for moderate to high risk of malignancy	August 31, 2017	October 1, 2017	CPT® 2019
OncoTarget/ OncoTreat, Columbia University Department of Pathology and Cell Biology, Darwin Health	●0019U	Oncology, RNA, gene expression by whole transcriptome sequencing, formalin-fixed paraffin-embedded tissue or fresh frozen tissue, predictive algorithm reported as potential targets for therapeutic agents	August 31, 2017	October 1, 2017	CPT® 2019
ToxLok, InSource Diagnostics, Agena Bioscience, Inc. InSource Diagnostics	●0020U	Drug test(s), presumptive, with definitive confirmation of positive results, any number of drug classes, urine, with specimen verification including DNA authentication in comparison to buccal DNA, per date of service ►(For additional PLA code with identical clinical descriptor, see 0007U. See Appendix O to determine appropriate code assignment)◄ ►(0020U has been deleted)◄	August 31, 2017 Deletion Released to AMA Website August 31, 2018	October 1, 2017 Deletion Effective October 1, 2018	CPT® 2019 Deletion Publication CPT® 2020
Apifyny®, Armune BioScience, Inc	●0021U	Oncology (prostate), detection of 8 autoantibodies (ARF 6, NKX3-1, 5'-UTR-BMI1, CEP 164, 3'-UTR-Ropporin, Desmocollin, AURKAIP-1, CSNK2A2), multiplexed immunoassay and flow cytometry serum, algorithm reported as risk score	August 31, 2017	October 1, 2017	CPT® 2019



OncoPrint™ Dx Target Test, Thermo Fisher Scientific	●0022U	Targeted genomic sequence analysis panel, non-small cell lung neoplasia, DNA and RNA analysis, 23 genes, interrogation for sequence variants and rearrangements, reported as presence/absence of variants and associated therapy(ies) to consider	August 31, 2017	October 1, 2017	CPT® 2019
LeukoStrat® CDx <i>FLT3</i> Mutation Assay, LabPMM LLC, an Invivoscribe Technologies, Inc Company, Invivoscribe Technologies, Inc	●0023U	Oncology (acute myelogenous leukemia), DNA, genotyping of internal tandem duplication, p.D835, p.I836, using mononuclear cells, reported as detection or non-detection of <i>FLT3</i> mutation and indication for or against the use of midostaurin	August 31, 2017	October 1, 2017	CPT® 2019
GlycA, Laboratory Corporation of America, Laboratory Corporation of America	●0024U	Glycosylated acute phase proteins (GlycA), nuclear magnetic resonance spectroscopy, quantitative	December 1, 2017	January 1, 2018	CPT® 2019
UrSure Tenofovir Quantification Test, Synergy Medical Laboratories, UrSure Inc	●0025U	Tenofovir, by liquid chromatography with tandem mass spectrometry (LC-MS/MS), urine, quantitative	December 1, 2017	January 1, 2018	CPT® 2019
Thyroseq Genomic Classifier, CBLPath, Inc, University of Pittsburgh Medical Center	●0026U	Oncology (thyroid), DNA and mRNA of 112 genes, next-generation sequencing, fine needle aspirate of thyroid nodule, algorithmic analysis reported as a categorical result ("Positive, high probability of malignancy" or "Negative, low probability of malignancy")	December 1, 2017	January 1, 2018	CPT® 2019
<i>JAK2</i> Exons 12 to 15 Sequencing, Mayo Clinic, Mayo Clinic	●0027U	<i>JAK2</i> (<i>Janus kinase 2</i>) (eg, myeloproliferative disorder) gene analysis, targeted sequence analysis exons 12-15	December 1, 2017	January 1, 2018	CPT® 2019

<i>CYP2D6</i> Genotype Cascade, Mayo Clinic, Mayo Clinic	●0028U	<i>CYP2D6</i> (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, copy number variants, common variants with reflex to targeted sequence analysis ▶(0028U has been deleted)◀	December 1, 2017 Deletion Released to AMA Website August 31, 2018	January 1, 2018 Deletion Effective October 1, 2018	CPT® 2019 Deletion Publication CPT® 2020
Focused Pharmacogenomics Panel, Mayo Clinic, Mayo Clinic	●0029U	Drug metabolism (adverse drug reactions and drug response), targeted sequence analysis (ie, <i>CYP1A2</i> , <i>CYP2C19</i> , <i>CYP2C9</i> , <i>CYP2D6</i> , <i>CYP3A4</i> , <i>CYP3A5</i> , <i>CYP4F2</i> , <i>SLCO1B1</i> , <i>VKORC1</i> and rs12777823)	December 1, 2017	January 1, 2018	CPT® 2019
Warfarin Response Genotype, Mayo Clinic, Mayo Clinic	●0030U	Drug metabolism (warfarin drug response), targeted sequence analysis (ie, <i>CYP2C9</i> , <i>CYP4F2</i> , <i>VKORC1</i> , rs12777823)	December 1, 2017	January 1, 2018	CPT® 2019
Cytochrome P450 1A2 Genotype, Mayo Clinic, Mayo Clinic	●0031U	<i>CYP1A2</i> (cytochrome P450 family 1, subfamily A, member 2) (eg, drug metabolism) gene analysis, common variants (ie, *1F, *1K, *6, *7)	December 1, 2017	January 1, 2018	CPT® 2019
Catechol-O-Methyltransferase (<i>COMT</i>) Genotype, Mayo Clinic, Mayo Clinic	●0032U	<i>COMT</i> (catechol-O-methyltransferase) (eg, drug metabolism) gene analysis, c.472G>A (rs4680) variant	December 1, 2017	January 1, 2018	CPT® 2019
Serotonin Receptor Genotype (<i>HTR2A</i> and <i>HTR2C</i>), Mayo Clinic, Mayo Clinic	●0033U	<i>HTR2A</i> (5-hydroxytryptamine receptor 2A), <i>HTR2C</i> (5-hydroxytryptamine receptor 2C) (eg, citalopram metabolism) gene analysis, common variants (ie, <i>HTR2A</i> rs7997012 [c.614-2211T>C], <i>HTR2C</i> rs3813929 [c.-759C>T] and rs1414334 [c.551-3008C>G])	December 1, 2017	January 1, 2018	CPT® 2019

Thiopurine Methyltransferase (<i>TPMT</i>) and Nudix Hydrolase (<i>NUDT15</i>) Genotyping, Mayo Clinic, Mayo Clinic	●0034U	<i>TPMT</i> (thiopurine <i>S</i> -methyltransferase), <i>NUDT15</i> (nudix hydroxylase 15) (eg, thiopurine metabolism) gene analysis, common variants (ie, <i>TPMT</i> *2, *3A, *3B, *3C, *4, *5, *6, *8, *12; <i>NUDT15</i> *3, *4, *5)	December 1, 2017	January 1, 2018	CPT® 2019
Real-time quaking-induced conversion for prion detection (RT-QuIC), National Prion Disease Pathology Surveillance Center	●0035U	Neurology (prion disease), cerebrospinal fluid, detection of prion protein by quaking-induced conformational conversion, qualitative	March 1, 2018	April 1, 2018	CPT® 2019
EXaCT-1 Whole Exome Testing, Lab of Oncology-Molecular Detection, Weill Cornell Medicine-Clinical Genomics Laboratory	●0036U	Exome (ie, somatic mutations), paired formalin-fixed paraffin-embedded tumor tissue and normal specimen, sequence analyses	March 1, 2018	April 1, 2018	CPT® 2019
FoundationOne CDx™ (F1CDx), Foundation Medicine, Inc, Foundation Medicine, Inc	●0037U	Targeted genomic sequence analysis, solid organ neoplasm, DNA analysis of 324 genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden	March 1, 2018	April 1, 2018	CPT® 2019
Sensieva™ Droplet 25OH Vitamin D2/D3 Microvolume LC/MS Assay, InSource Diagnostics, InSource Diagnostics	●0038U	Vitamin D, 25 hydroxy D2 and D3, by LC-MS/MS, serum microsample, quantitative	March 1, 2018	April 1, 2018	CPT® 2019
Anti-dsDNA, High Salt/Avidity, University of Washington, Department of Laboratory Medicine, Bio-Rad	●0039U	Deoxyribonucleic acid (DNA) antibody, double stranded, high avidity	March 1, 2018	April 1, 2018	CPT® 2019

MRDx BCR-ABL Test, MolecularMD, MolecularMD	●0040U	<i>BCR/ABL1 (t(9;22))</i> (eg, chronic myelogenous leukemia) translocation analysis, major breakpoint, quantitative	March1, 2018	April 1, 2018	CPT® 2019
Lyme ImmunoBlot IgM, IGeneX Inc, ID-FISH Technology Inc. (ASR) (Lyme ImmunoBlot IgM Strips Only)	●0041U	<i>Borrelia burgdorferi</i> , antibody detection of 5 recombinant protein groups, by immunoblot, IgM	March1, 2018	April 1, 2018	CPT® 2019
Lyme ImmunoBlot IgG, IGeneX Inc, ID-FISH Technology Inc (ASR) (Lyme ImmunoBlot IgG Strips Only)	●0042U	<i>Borrelia burgdorferi</i> , antibody detection of 12 recombinant protein groups, by immunoblot, IgG	March1, 2018	April 1, 2018	CPT® 2019
Tick-Borne Relapsing Fever (TBRF) <i>Borrelia</i> ImmunoBlots IgM Test, IGeneX Inc, ID-FISH Technology Inc (Provides TBRF ImmunoBlot IgM Strips)	●0043U	Tick-borne relapsing fever <i>Borrelia</i> group, antibody detection to 4 recombinant protein groups, by immunoblot, IgM	March1, 2018	April 1, 2018	CPT® 2019
Tick-Borne Relapsing Fever (TBRF) <i>Borrelia</i> ImmunoBlots IgG Test, IGeneX Inc., ID-FISH Technology Inc (Provides TBRF ImmunoBlot IgG Strips)	●0044U	Tick-borne relapsing fever <i>Borrelia</i> group, antibody detection to 4 recombinant protein groups, by immunoblot, IgG	March1, 2018	April 1, 2018	CPT® 2019
The Oncotype DX® Breast DCIS Score™ Test, Genomic Health, Inc, Genomic Health, Inc	●0045U	Oncology (breast ductal carcinoma in situ), mRNA, gene expression profiling by real-time RT-PCR of 12 genes (7 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as recurrence score	June 1, 2018	July 1, 2018	CPT® 2019

FLT3 ITD MRD by NGS, LabPMM LLC, an Invivoscribe Technologies, Inc Company	●0046U	<i>FLT3 (fms-related tyrosine kinase 3)</i> (eg, acute myeloid leukemia) internal tandem duplication (ITD) variants, quantitative	June 1, 2018	July 1, 2018	CPT® 2019
Oncotype DX Genomic Prostate Score, Genomic Health, Inc, Genomic Health, Inc	●0047U	Oncology (prostate), mRNA, gene expression profiling by real-time RT-PCR of 17 genes (12 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a risk score	June 1, 2018	July 1, 2018	CPT® 2019
MSK-IMPACT (Integrated Mutation Profiling of Actionable Cancer Targets), Memorial Sloan Kettering Cancer Center	●0048U	Oncology (solid organ neoplasia), DNA, targeted sequencing of protein-coding exons of 468 cancer-associated genes, including interrogation for somatic mutations and microsatellite instability, matched with normal specimens, utilizing formalin-fixed paraffin-embedded tumor tissue, report of clinically significant mutation(s)	June 1, 2018	July 1, 2018	CPT® 2019
<i>NPM1</i> MRD by NGS, LabPMM LLC, an Invivoscribe Technologies, Inc Company	●0049U	<i>NPM1 (nucleophosmin)</i> (eg, acute myeloid leukemia) gene analysis, quantitative	June 1, 2018	July 1, 2018	CPT® 2019
MyAML NGS Panel, LabPMM LLC, an Invivoscribe Technologies, Inc Company	●0050U	Targeted genomic sequence analysis panel, acute myelogenous leukemia, DNA analysis, 194 genes, interrogation for sequence variants, copy number variants or rearrangements	June 1, 2018	July 1, 2018	CPT® 2019
UCompliDx, Elite Medical Laboratory Solutions, LLC, Elite Medical Laboratory Solutions, LLC (LDT)	●0051U	Prescription drug monitoring, evaluation of drugs present by LC-MS/MS, urine, 31 drug panel, reported as quantitative results, detected or not detected, per date of service	June 1, 2018	July 1, 2018	CPT® 2019



VAP Cholesterol Test, VAP Diagnostics Laboratory, Inc, VAP Diagnostics Laboratory, Inc	●0052U	Lipoprotein, blood, high resolution fractionation and quantitation of lipoproteins, including all five major lipoprotein classes and subclasses of HDL, LDL, and VLDL by vertical auto profile ultracentrifugation	June 1, 2018	July 1, 2018	CPT® 2019
Prostate Cancer Risk Panel, Mayo Clinic, Laboratory Developed Test	●0053U	Oncology (prostate cancer), FISH analysis of 4 genes (<i>ASAP1</i> , <i>HDAC9</i> , <i>CHD1</i> and <i>PTEN</i>), needle biopsy specimen, algorithm reported as probability of higher tumor grade	June 1, 2018	July 1, 2018	CPT® 2019
AssuranceRx Micro Serum, Firstox Laboratories, LLC, Firstox Laboratories, LLC	●0054U	Prescription drug monitoring, 14 or more classes of drugs and substances, definitive tandem mass spectrometry with chromatography, capillary blood, quantitative report with therapeutic and toxic ranges, including steady-state range for the prescribed dose when detected, per date of service	June 1, 2018	July 1, 2018	CPT® 2019
myTAIHEART, TAI Diagnostics, Inc, TAI Diagnostics, Inc	●0055U	Cardiology (heart transplant), cell-free DNA, PCR assay of 96 DNA target sequences (94 single nucleotide polymorphism targets and two control targets), plasma	June 1, 2018	July 1, 2018	CPT® 2019
MatePair Acute Myeloid Leukemia Panel, Mayo Clinic, Laboratory Developed Test	●0056U	Hematology (acute myelogenous leukemia), DNA, whole genome next-generation sequencing to detect gene rearrangement(s), blood or bone marrow, report of specific gene rearrangement(s)	June 1, 2018	July 1, 2018	CPT® 2019
RNA-Sequencing by NGS, OmniSeq, Inc, Life Technologies Corporation	●0057U	Oncology (solid organ neoplasia), mRNA, gene expression profiling by massively parallel sequencing for analysis of 51 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a normalized percentile rank	June 1, 2018	July 1, 2018	CPT® 2019

Merkel SmT Oncoprotein Antibody Titer, University of Washington, Department of Laboratory Medicine	●0058U	Oncology (Merkel cell carcinoma), detection of antibodies to the Merkel cell polyoma virus oncoprotein (small T antigen), serum, quantitative	June 1, 2018	July 1, 2018	CPT® 2019
Merkel Virus VP1 Capsid Antibody, University of Washington, Department of Laboratory Medicine	●0059U	Oncology (Merkel cell carcinoma), detection of antibodies to the Merkel cell polyoma virus capsid protein (VP1), serum, reported as positive or negative	June 1, 2018	July 1, 2018	CPT® 2019
Twins Zygosity PLA, Natera, Inc, Natera, Inc	●0060U	Twin zygosity, genomic-targeted sequence analysis of chromosome 2, using circulating cell-free fetal DNA in maternal blood	June 1, 2018	July 1, 2018	CPT® 2019
Transcutaneous multispectral measurement of tissue oxygenation and hemoglobin using spatial frequency domain imaging (SFDI), Modulated Imaging, Inc, Modulated Imaging, Inc	●0061U	Transcutaneous measurement of five biomarkers (tissue oxygenation [StO ₂], oxyhemoglobin [ctHbO ₂], deoxyhemoglobin [ctHbR], papillary and reticular dermal hemoglobin concentrations [ctHb1 and ctHb2]), using spatial frequency domain imaging (SFDI) and multi-spectral analysis	June 1, 2018	July 1, 2018	CPT® 2019
SLE-key® Rule Out, Veracis Inc, Veracis Inc	●0062U	Autoimmune (systemic lupus erythematosus), IgG and IgM analysis of 80 biomarkers, utilizing serum, algorithm reported with a risk score	August 31, 2018	October 1, 2018	CPT® 2020
NPDX ASD ADM Panel I, Stemina Biomarker Discovery, Inc, Stemina Biomarker Discovery, Inc d/b/a NeuroPointDX	●0063U	Neurology (autism), 32 amines by LC-MS/MS, using plasma, algorithm reported as metabolic signature associated with autism spectrum disorder	August 31, 2018	October 1, 2018	CPT® 2020



BioPlex 2200 Syphilis Total & RPR Assay, Bio-Rad Laboratories, Bio-Rad Laboratories	●0064U	Antibody, Treponema pallidum, total and rapid plasma reagin (RPR), immunoassay, qualitative	August 31, 2018	October 1, 2018	CPT® 2020
BioPlex 2200 RPR Assay, Bio-Rad Laboratories, Bio-Rad Laboratories	●0065U	Syphilis test, non-treponemal antibody, immunoassay, qualitative (RPR)	August 31, 2018	October 1, 2018	CPT® 2020
PartoSure™ Test, Parsagen Diagnostics, Inc, Parsagen Diagnostics, Inc, a QIAGEN Company	●0066U	Placental alpha-micro globulin-1 (PAMG-1), immunoassay with direct optical observation, cervico-vaginal fluid, each specimen	August 31, 2018	October 1, 2018	CPT® 2020
BBDRisk Dx™, Silbiotech, Inc	●0067U	Oncology (breast), immunohistochemistry, protein expression profiling of 4 biomarkers (matrix metalloproteinase-1 [MMP-1], carcinoembryonic antigen-related cell adhesion molecule 6 [CEACAM6], hyaluronoglucosaminidase [HYAL1], highly expressed in cancer protein [HEC1]), formalin-fixed paraffin-embedded precancerous breast tissue, algorithm reported as carcinoma risk score	August 31, 2018	October 1, 2018	CPT® 2020
MYCODART Dual Amplification Real Time PCR Panel for 6 Candida species, RealTime Laboratories, Inc	●0068U	Candida species panel (<i>C. albicans</i> , <i>C. glabrata</i> , <i>C. parapsilosis</i> , <i>C. kruseii</i> , <i>C. tropicalis</i> , and <i>C. auris</i>), amplified probe technique with qualitative report of the presence or absence of each species	August 31, 2018	October 1, 2018	CPT® 2020
miR-31now™, GoPath Laboratories, GoPath Laboratories	●0069U	Oncology (colorectal), microRNA, RT-PCR expression profiling of miR-31-3p, formalin-fixed paraffin-embedded tissue, algorithm reported as an expression score	August 31, 2018	October 1, 2018	CPT® 2020

<p><i>CYP2D6</i> Common Variants and Copy Number, Mayo Clinic, Laboratory Developed Test</p>	<p>●0070U</p>	<p><i>CYP2D6</i> (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, common and select rare variants (ie, *2, *3, *4, *4N, *5, *6, *7, *8, *9, *10, *11, *12, *13, *14A, *14B, *15, *17, *29, *35, *36, *41, *57, *61, *63, *68, *83, *xN)</p>	<p>August 31, 2018</p>	<p>October 1, 2018</p>	<p>CPT® 2020</p>
<p><i>CYP2D6</i> Full Gene Sequencing, Mayo Clinic, Laboratory Developed Test</p>	<p>+●0071U</p>	<p><i>CYP2D6</i> (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, full gene sequence (List separately in addition to code for primary procedure)</p> <p>▶(Use 0071U in conjunction with 0070U)◀</p>	<p>August 31, 2018</p>	<p>October 1, 2018</p>	<p>CPT® 2020</p>
<p><i>CYP2D6-2D7</i> Hybrid Gene Targeted Sequence Analysis, Mayo Clinic, Laboratory Developed Test</p>	<p>+●0072U</p>	<p><i>CYP2D6</i> (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, <i>CYP2D6-2D7</i> hybrid gene) (List separately in addition to code for primary procedure)</p> <p>▶(Use 0072U in conjunction with 0070U)◀</p>	<p>August 31, 2018</p>	<p>October 1, 2018</p>	<p>CPT® 2020</p>
<p><i>CYP2D7-2D6</i> Hybrid Gene Targeted Sequence Analysis, Mayo Clinic, Laboratory Developed Test</p>	<p>+●0073U</p>	<p><i>CYP2D6</i> (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, <i>CYP2D7-2D6</i> hybrid gene) (List separately in addition to code for primary procedure)</p> <p>▶(Use 0073U in conjunction with 0070U)◀</p>	<p>August 31, 2018</p>	<p>October 1, 2018</p>	<p>CPT® 2020</p>
<p><i>CYP2D6</i> trans-duplication/multiplication non-duplicated gene targeted sequence analysis, Mayo Clinic, Laboratory Developed Test</p>	<p>+●0074U</p>	<p><i>CYP2D6</i> (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, non-duplicated gene when duplication/multiplication is trans) (List separately in addition to code for primary procedure)</p> <p>▶(Use 0074U in conjunction with 0070U)◀</p>	<p>August 31, 2018</p>	<p>October 1, 2018</p>	<p>CPT® 2020</p>
<p><i>CYP2D6</i> 5' gene duplication/multiplication targeted sequence analysis, Mayo Clinic, Laboratory Developed Test</p>	<p>+●0075U</p>	<p><i>CYP2D6</i> (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, 5' gene duplication/multiplication) (List separately in addition to code for primary procedure)</p> <p>▶(Use 0075U in conjunction with 0070U)◀</p>	<p>August 31, 2018</p>	<p>October 1, 2018</p>	<p>CPT® 2020</p>

CYP2D6 3' gene duplication/ multiplication targeted sequence analysis, Mayo Clinic, Laboratory Developed Test	+●0076U	CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, 3' gene duplication/multiplication) (List separately in addition to code for primary procedure) ▶(Use 0076U in conjunction with 0070U)◀	August 31, 2018	October 1, 2018	CPT® 2020
M-Protein Detection and Isotyping by MALDI-TOF Mass Spectrometry, Mayo Clinic, Laboratory Developed Test	●0077U	Immunoglobulin paraprotein (M-protein), qualitative, immunoprecipitation and mass spectrometry, blood or urine, including isotype	August 31, 2018	October 1, 2018	CPT® 2020
INFINITI® Neural Response Panel, PersonalizeDx Labs, AutoGenomics Inc	●0078U	Pain management (opioid-use disorder) genotyping panel, 16 common variants (ie, ABCB1, COMT, DAT1, DBH, DOR, DRD1, DRD2, DRD4, GABA, GAL, HTR2A, HTTLPR, MTHFR, MUOR, OPRK1, OPRM1), buccal swab or other germline tissue sample, algorithm reported as positive or negative risk of opioid-use disorder	August 31, 2018	October 1, 2018	CPT® 2020
ToxLok™, InSource Diagnostics, InSource Diagnostics	●0079U	Comparative DNA analysis using multiple selected single-nucleotide polymorphisms (SNPs), urine and buccal DNA, for specimen identity verification	August 31, 2018	October 1, 2018	CPT® 2020
BDX-XL2, Bodesix®, Inc	●0080U	Oncology (lung), mass spectrometric analysis of galectin-3-binding protein and scavenger receptor cysteine-rich type 1 protein M130, with five clinical risk factors (age, smoking status, nodule diameter, nodule-spiculation status and nodule location), utilizing plasma, algorithm reported as a categorical probability of malignancy	November 30, 2018	January 1, 2019	CPT® 2020
DecisionDx®-UM, Castle Biosciences, Inc	●0081U	Oncology (uveal melanoma), mRNA, gene-expression profiling by real-time RT-PCR of 15 genes (12 content and 3 housekeeping genes), utilizing fine needle aspirate or formalin-fixed paraffin-embedded tissue, algorithm reported as risk of metastasis	November 30, 2018	January 1, 2019	CPT® 2020



NextGen Precision™ Testing, Precision Diagnostics LBN Precision Toxicology, LLC	●0082U	Drug test(s), definitive, 90 or more drugs or substances, definitive chromatography with mass spectrometry, and presumptive, any number of drug classes, by instrument chemistry analyzer (utilizing immunoassay), urine, report of presence or absence of each drug, drug metabolite or substance with description and severity of significant interactions per date of service	November 30, 2018	January 1, 2019	CPT® 2020
Onco4D™, Animated Dynamics, Inc	●0083U	Oncology, response to chemotherapy drugs using motility contrast tomography, fresh or frozen tissue, reported as likelihood of sensitivity or resistance to drugs or drug combinations	November 30, 2018	January 1, 2019	CPT® 2020